Stock Research for ECYT

ECYT

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ECYT Stock Chart & Research Data

The ECYT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ECYT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ECYT Due diligence Resources & Stock Charts

The ECYT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ECYT Detailed Price Forecast - CNN Money CNN View ECYT Detailed Summary - Google Finance
Yahoo View ECYT Detailed Summary - Yahoo! Finance Zacks View ECYT Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ECYT Trends & Analysis - Trade-Ideas Barrons View ECYT Major Holders - Barrons
NASDAQ View ECYT Call Transcripts - NASDAQ Seeking View ECYT Breaking News & Analysis - Seeking Alpha
Spotlight View ECYT Annual Report - CompanySpotlight.com OTC Report View ECYT OTC Short Report - OTCShortReport.com
TradeKing View ECYT Fundamentals - TradeKing Charts View ECYT SEC Filings - Bar Chart
WSJ View Historical Prices for ECYT - The WSJ Morningstar View Performance/Total Return for ECYT - Morningstar
MarketWatch View the Analyst Estimates for ECYT - MarketWatch CNBC View the Earnings History for ECYT - CNBC
StockMarketWatch View the ECYT Earnings - StockMarketWatch MacroAxis View ECYT Buy or Sell Recommendations - MacroAxis
Bullish View the ECYT Bullish Patterns - American Bulls Short Pains View ECYT Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ECYT Stock Mentions - StockTwits PennyStocks View ECYT Stock Mentions - PennyStockTweets
Twitter View ECYT Stock Mentions - Twitter Invest Hub View ECYT Investment Forum News - Investor Hub
Yahoo View ECYT Stock Mentions - Yahoo! Message Board Seeking Alpha View ECYT Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ECYT - SECform4.com Insider Cow View Insider Transactions for ECYT - Insider Cow
CNBC View ECYT Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ECYT - OTC Markets
Yahoo View Insider Transactions for ECYT - Yahoo! Finance NASDAQ View Institutional Holdings for ECYT - NASDAQ


Stock Charts

FinViz View ECYT Stock Insight & Charts - FinViz.com StockCharts View ECYT Investment Charts - StockCharts.com
BarChart View ECYT Stock Overview & Charts - BarChart Trading View View ECYT User Generated Charts - Trading View




Latest Financial News for ECYT


This tiny biotech spun a quick $2 billion from $12 million
Posted on Monday October 22, 2018

Endocyte licensed a prostate cancer drug a year ago for an upfront payment of $12 million. Now, it’s being bought by the Swiss pharma giant Novartis for more than $2 billion.


Can The Uptrend Continue for Endocyte (ECYT)?
Posted on Friday October 19, 2018

Investors certainly have to be happy with Endocyte, Inc. (ECYT) and its short term performance.


The Daily Biotech Pulse: Novartis Positive Liver Drug Trials, Krytstal Prices Offering, LogicBio To Debut
Posted on Friday October 19, 2018

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 18) Endocyte, Inc. (NASDAQ: ECYT )( announced a deal to ...


Today’s Research Reports on Stocks to Watch: Proteostasis Therapeutics and Endocyte
Posted on Friday October 19, 2018

NEW YORK, NY / ACCESSWIRE / October 19, 2018 / Shares of biotech stocks Proteostasis Therapeutics and Endocyte were seeing big gains on different exciting announcements. Proteostasis announced encouraging preliminary results while traders learned that Endocyte will be purchased by Novartis for $2.1 billion. Proteostasis Therapeutics, Inc. shares closed up 447.62% on Thursday on skyrocket volume of about 94 million shares.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.